Argenx (ARGX) has released an update.
Argenx has announced promising data from the ADHERE trial for its drug VYVGART Hytrulo, potentially offering a significant treatment advancement for patients with chronic inflammatory demyelinating polyneuropathy (CIDP)—the first in 30 years. The trial results, presented at the AAN Annual Meeting, show a 61% reduction in relapse risk and indicate the drug’s ability to produce rapid and sustained clinical improvement. Additionally, real-world evidence suggests that VYVGART can enable gMG patients to substantially reduce steroid use within the first six months of treatment.
For further insights into ARGX stock, check out TipRanks’ Stock Analysis page.
